Additionally, nintedanib, an approved treatment of idiopathic pulmonary fibrosis, has been identified as a dual inhibitor of MDM2 and MDM4, disrupting their interaction with p53 and leading to growth inhibition in p53-positive cancer cells [38]. The gene discussed is TP53; the disease is pulmonary fibrosis.